Diphtheria & Tetanus Antibodies, IgG
0050595
Ordering Recommendation
Evaluate the ability of a patient to produce antibody to pure protein vaccines after vaccination to rule out antibody deficiency.
Mnemonic
D/T
Methodology
Quantitative Multiplex Bead Assay
Performed
Sun-Sat
Reported
1-2 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
- Patient Preparation
- Collect
- Serum separator tube. "Pre" and "post" vaccination specimens should be submitted for testing. "Post" specimen should be drawn 30 days after immunization.
- Specimen Preparation
- Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL) Mark specimens clearly as "Pre-Vaccine" or "Post-Vaccine". If shipped separately, "Post" specimen must be received within 60 days of "Pre" specimen.
- Storage/Transport Temperature
- Refrigerated
- Unacceptable Conditions
- Plasma or other body fluids.
- Remarks
- Stability
- After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Reference Interval
Antibody concentrations of > 0.1 IU/mL are usually considered protective for diphtheria or tetanus.
Interpretive Data
Responder status is determined according to the ratio of a one-month post-vaccination sample to pre-vaccination concentration of IgG antibodies as follows:
Diphtheria and tetanus:
1. If the post-vaccination concentration is less than 1.0 IU/mL, the patient is considered a nonresponder.
2. If the post-vaccination concentration is greater than or equal to 1.0 IU/mL, a patient with a ratio of less than 1.5 is a nonresponder, a ratio of 1.5 to less than 3.0, is a weak responder, and a ratio of 3.0 or greater, is a good responder.
3. If the pre-vaccination concentration is greater than 1.0 IU/mL, it may be difficult to assess the response based on a ratio alone. A post-vaccination concentration above 2.5 IU in this case is adequate.
Diphtheria and tetanus:
1. If the post-vaccination concentration is less than 1.0 IU/mL, the patient is considered a nonresponder.
2. If the post-vaccination concentration is greater than or equal to 1.0 IU/mL, a patient with a ratio of less than 1.5 is a nonresponder, a ratio of 1.5 to less than 3.0, is a weak responder, and a ratio of 3.0 or greater, is a good responder.
3. If the pre-vaccination concentration is greater than 1.0 IU/mL, it may be difficult to assess the response based on a ratio alone. A post-vaccination concentration above 2.5 IU in this case is adequate.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0050210 | Diphtheria Antibody, IgG | 13227-4 |
| 0050535 | Tetanus Antibody, IgG | 53935-3 |
Aliases
- C. tetani
- Clostridium tetani
- Corynebacterium diphtheriae Antitoxin
- Diphtheria Antitoxoid
- Immune Response
- nti-tetanus toxoid
- Tetanus Immune Response
- Tetanus toxoid antibodies
- Tetanus/Diphtheria Antibody Panel
- Tetanus/Diptheria Vaccine Response
- Vaccine Response